Mavacamten

Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Camzyos and mavacamtenum. Its PubChem CID is 117761397.

CAS No 1642288-47-8
Molecular Formula C15H19N3O2
Molecular Weight 273.33 g/mol
Synonyms 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione

Frequently Asked Questions